Tags

Type your tag names separated by a space and hit enter

Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin.

Abstract

Evaluation of the efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit (LTB) containing a trace amount of the holotoxin (LT) in inducing antibody responses among volunteers, which was conducted during the winter season of 1993-1994, is reported. A trivalent inactivated vaccine, composed of A/Yamagata/32/89 (H1N1), A/Kitakyusyu/159/93 (H3N2) and B/Bangkok/163/90 influenza virus strains, was used alone or together with the adjuvant, recombinant LTB supplemented with 0.5% recombinant LT (LTB*). The volunteers were divided into two groups: 73 volunteers (mean age 35.0 +/- 12.0 years) inoculated intranasally (i.n.) with LTB*-combined vaccine and 49 volunteers (37.9 +/- 11.3) inoculated i.n. with the vaccine alone. Vaccination was done twice 4 weeks apart. Salivary secretory IgA and serum hemagglutination-inhibiting (HI) antibodies were measured before and 8 weeks after the primary vaccination. For the sake of convenience, more than a 1.4-fold rise in IgA antibody response (units of specific IgA antibody per microgram of total IgA) and a fourfold or greater rise in HI antibody titer after vaccination were regarded as a positive antibody response. Thirty-seven (50.3%) and 36 (49.3%) of the 73 vaccinees, respectively, given the nasal LTB*-combined vaccine showed positive IgA and HI antibody responses to one or more of the three vaccine strains. In comparison, positive antibody responses in the group given vaccine alone were 32.7% for IgA and 30.6% for HI antibody. There was a significant difference between these two groups. These results suggest that the nasal LTB*-combined vaccine could enhance the production of higher levels not only of serum HI antibody but IgA antibodies in the respiratory tract than do the nasal vaccine alone.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    E.N.T. Department, Kitasato Institute Hospital, Tokyo, Japan.

    , , , , , , , , , , , ,

    Source

    Vaccine 14:2 1996 Feb pg 113-9

    MeSH

    Adjuvants, Immunologic
    Administration, Intranasal
    Adult
    Antibodies, Viral
    Bacterial Toxins
    Enterotoxins
    Escherichia coli
    Escherichia coli Proteins
    Female
    Glycosides
    Hemagglutination Inhibition Tests
    Hemagglutinins, Viral
    Humans
    Immunoglobulin A
    Immunoglobulin A, Secretory
    Influenza Vaccines
    Male
    Middle Aged
    Radiation-Sensitizing Agents
    Saliva
    Triterpenes
    Vaccines, Combined

    Pub Type(s)

    Comparative Study
    Journal Article

    Language

    eng

    PubMed ID

    8852406

    Citation

    Hashigucci, K, et al. "Antibody Responses in Volunteers Induced By Nasal Influenza Vaccine Combined With Escherichia Coli Heat-labile Enterotoxin B Subunit Containing a Trace Amount of the Holotoxin." Vaccine, vol. 14, no. 2, 1996, pp. 113-9.
    Hashigucci K, Ogawa H, Ishidate T, et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine. 1996;14(2):113-9.
    Hashigucci, K., Ogawa, H., Ishidate, T., Yamashita, R., Kamiya, H., Watanabe, K., ... Oya, A. (1996). Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine, 14(2), pp. 113-9.
    Hashigucci K, et al. Antibody Responses in Volunteers Induced By Nasal Influenza Vaccine Combined With Escherichia Coli Heat-labile Enterotoxin B Subunit Containing a Trace Amount of the Holotoxin. Vaccine. 1996;14(2):113-9. PubMed PMID: 8852406.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. AU - Hashigucci,K, AU - Ogawa,H, AU - Ishidate,T, AU - Yamashita,R, AU - Kamiya,H, AU - Watanabe,K, AU - Hattori,N, AU - Sato,T, AU - Suzuki,Y, AU - Nagamine,T, AU - Aizawa,C, AU - Tamura,S, AU - Kurata,T, AU - Oya,A, PY - 1996/2/1/pubmed PY - 1996/2/1/medline PY - 1996/2/1/entrez SP - 113 EP - 9 JF - Vaccine JO - Vaccine VL - 14 IS - 2 N2 - Evaluation of the efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit (LTB) containing a trace amount of the holotoxin (LT) in inducing antibody responses among volunteers, which was conducted during the winter season of 1993-1994, is reported. A trivalent inactivated vaccine, composed of A/Yamagata/32/89 (H1N1), A/Kitakyusyu/159/93 (H3N2) and B/Bangkok/163/90 influenza virus strains, was used alone or together with the adjuvant, recombinant LTB supplemented with 0.5% recombinant LT (LTB*). The volunteers were divided into two groups: 73 volunteers (mean age 35.0 +/- 12.0 years) inoculated intranasally (i.n.) with LTB*-combined vaccine and 49 volunteers (37.9 +/- 11.3) inoculated i.n. with the vaccine alone. Vaccination was done twice 4 weeks apart. Salivary secretory IgA and serum hemagglutination-inhibiting (HI) antibodies were measured before and 8 weeks after the primary vaccination. For the sake of convenience, more than a 1.4-fold rise in IgA antibody response (units of specific IgA antibody per microgram of total IgA) and a fourfold or greater rise in HI antibody titer after vaccination were regarded as a positive antibody response. Thirty-seven (50.3%) and 36 (49.3%) of the 73 vaccinees, respectively, given the nasal LTB*-combined vaccine showed positive IgA and HI antibody responses to one or more of the three vaccine strains. In comparison, positive antibody responses in the group given vaccine alone were 32.7% for IgA and 30.6% for HI antibody. There was a significant difference between these two groups. These results suggest that the nasal LTB*-combined vaccine could enhance the production of higher levels not only of serum HI antibody but IgA antibodies in the respiratory tract than do the nasal vaccine alone. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/8852406/Antibody_responses_in_volunteers_induced_by_nasal_influenza_vaccine_combined_with_Escherichia_coli_heat_labile_enterotoxin_B_subunit_containing_a_trace_amount_of_the_holotoxin_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0264410X9500174Y DB - PRIME DP - Unbound Medicine ER -